Cervical cancer: Critical role of vaccination and screening

Updated / Tuesday, 17 Nov 2026 10:24 A health worker administers human papillomavirus (HPV) vaccine to a girl in Karachi on September 24, 2025, during a HPV vaccination drive against cervical cancer, most frequently diagnosed in women (RIZWAN TABASSUM / AFP) We need your consent to load this EBU content We use EBU to manage extra content that can set cookies on your device and collect data about your activity. Please review their details and accept them to load the content. Manage Preferences The World Health Organization (WHO) has established 17 November as the World Day for the Elimination of Cervical Cancer, highlighting the unique opportunity that scientific progress offers today to eliminate cervical cancer as a public health problem. The day coincides with the launch of an ambitious global strategy in 2020, based on HPV vaccination, systematic screening and timely, effective therapeutic management. The ultimate goal is to dramatically reduce new cases and deaths from the disease. Doctors from the Therapeutic Clinic (Alexandra Hospital) of the Medical School of EKPA Dr. Maria Kaperelou (Internist – Oncologist) and Thanos Dimopoulos (Professor of Therapeutics – Oncology – Hematology, Director of the Therapeutic Clinic, Alexandra Hospital, former Rector of EKPA) report that, according to updated WHO data, 604,000 new cases of cervical cancer and 280,000 deaths were recorded worldwide in 2024. Despite significant scientific advances, the disease remains a major threat to public health, particularly in countries where access to vaccination and screening remains limited. The development of cervical cancer is almost always linked to persistent infection by oncogenic types of human papillomavirus (HPV), mainly types 16 and 18. HPV is a highly common sexually transmitted virus. In most cases, the infection resolves automatically through the action of the immune system. However, the persistence of certain oncogenic types may lead to the development of precancerous lesions, which may evolve into invasive cancer after several years. According to experts, vaccination is the most important primary prevention measure. Available vaccines offer high protection against the main oncogenic types of the virus and significantly reduce the risk of developing precancerous lesions and cancer. Vaccination is recommended preferentially before the onset of sexual activity and is advised for both girls and boys, serving as an important preventive measure against HPV-related malignancies for both sexes. Screening is equally vital, through Pap tests and molecular HPV DNA testing, according to current guidelines. These tests allow for the identification of precancerous lesions or high-risk infections before symptoms appear. Timely management of precancerous lesions can prevent their progression to cancer. It is worth noting that vaccination does not replace screening, as both interventions work complementarily. Cervical cancer often does not cause symptoms in the early stages. The appearance of unusual vaginal bleeding, particularly after sexual intercourse or menopause, persistent unusual discharge, or pelvic pain requires immediate gynecological investigation. Significant progress has also been made in the therapeutic management of the disease, report scientists from EKPA. At early stages, surgical treatment can provide a cure, while in locally advanced disease, chemoradiotherapy is a key treatment pillar. In recent years, immunotherapy has changed the treatment landscape. The KEYNOTE-A18 study demonstrated significant improvement in overall survival with the addition of pembrolizumab to chemoradiotherapy and its continuation as maintenance therapy in patients with high-risk locally advanced disease. Meanwhile, the KEYNOTE-826 study showed significant survival benefit from the addition of pembrolizumab to chemotherapy, with or without bevacizumab, in patients with persistent, recurrent, or metastatic disease, especially when the tumor expresses PD-L1. WHO has set a goal for 2030 to fully vaccinate 90% of girls by the age of 15, conduct screening for 70% of women by ages 35 and 45, and provide appropriate treatment for 90% of women with precancerous lesions or invasive cancer. "November 17 serves as a reminder that the elimination of cervical cancer as a public health problem is no longer a distant scientific vision, but a realistic goal. Education, vaccination, systematic preventive screening, and equitable access to modern treatments can save thousands of lives. "For the first time, we have the opportunity to fundamentally change the course of malignancy by treating it more effectively and preventing its occurrence," conclude the EKPA experts. An article written by ERTNews, initially published on 17 November 2026, 09:24 (CET)